- Home
- NGNE vs HURA Comparison
NGNE vs HURA Comparison
Compare NGNE & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- HURA
- Stock Information
- Founded
- NGNE 2003
- HURA 2009
- Country
- NGNE United States
- HURA United States
- Employees
- NGNE N/A
- HURA N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- HURA
- Sector
- NGNE Health Care
- HURA
- Exchange
- NGNE Nasdaq
- HURA Nasdaq
- Market Cap
- NGNE 230.0M
- HURA 246.9M
- IPO Year
- NGNE N/A
- HURA N/A
- Fundamental
- Price
- NGNE $17.36
- HURA $3.33
- Analyst Decision
- NGNE Strong Buy
- HURA Strong Buy
- Analyst Count
- NGNE 6
- HURA 1
- Target Price
- NGNE $60.80
- HURA $11.00
- AVG Volume (30 Days)
- NGNE 277.9K
- HURA 216.5K
- Earning Date
- NGNE 11-18-2024
- HURA 03-04-2025
- Dividend Yield
- NGNE N/A
- HURA N/A
- EPS Growth
- NGNE N/A
- HURA N/A
- EPS
- NGNE N/A
- HURA N/A
- Revenue
- NGNE $925,000.00
- HURA N/A
- Revenue This Year
- NGNE N/A
- HURA N/A
- Revenue Next Year
- NGNE N/A
- HURA N/A
- P/E Ratio
- NGNE N/A
- HURA N/A
- Revenue Growth
- NGNE N/A
- HURA N/A
- 52 Week Low
- NGNE $14.42
- HURA $2.84
- 52 Week High
- NGNE $74.49
- HURA $14.60
- Technical
- Relative Strength Index (RSI)
- NGNE 44.25
- HURA N/A
- Support Level
- NGNE $16.72
- HURA N/A
- Resistance Level
- NGNE $19.97
- HURA N/A
- Average True Range (ATR)
- NGNE 2.39
- HURA 0.00
- MACD
- NGNE 0.08
- HURA 0.00
- Stochastic Oscillator
- NGNE 19.43
- HURA 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.